TTUHSC researchers publish preclinical data on new drug combination to treat neuroblastoma

(Texas Tech University Health Sciences Center) Neuroblastoma, the most common cancer outside of the brain in infants and young children, often fails to respond to therapy. To improve treatment outcomes for these patients, C. Patrick Reynolds, M.D., Ph.D., director of the Texas Tech University Health Sciences Center School of Medicine's Cancer Center, and a team of colleagues completed a study using fenretinide to boost the effects of venetoclax, an inhibitor of a protein (BCL-2) that helps neuroblastoma cells survive and grow.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news